EphA2 and EphA3 Maintain Tumour Initiating Cells and are Therapeutic Targets in Brain Cancer [ 2015 - 2017 ]

Research Grant

Researchers: Dr Bryan Day (Principal investigator)

Brief description High-grade glioma (HGG) is the most common adult brain cancer; current treatments have increased survival times by months only. Our studies have shown brain cancer specific expression of a family of cell surface proteins called Eph receptors. Furthermore we have shown targeting these receptors with Eph antibodies leads to a significant reduction in brain cancer tumour growth. We now propose to test targeting these receptors in combination to achieve greater responses with minimal side effects.

Funding Amount $AUD 612,860.30

Funding Scheme Project Grants

Notes New Investigator Grant